Ric kayne publishes investor presentation highlighting urgent need for changes to athira's board of directors

New york--(business wire)--richard a. (ric) kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of athira pharma, inc. (nasdaq: atha) (“athira” or the “company”), today released a detailed presentation to athira's shareholders demonstrating the need for immediate change on the company's board of directors (the “board”) to properly oversee the clinical trials for ath-1017 and preserve the value of shareholders' investment. the pr
ATHA Ratings Summary
ATHA Quant Ranking